Katja Weisel

Katja Weisel

UNVERIFIED PROFILE

Are you Katja Weisel?   Register this Author

Register author
Katja Weisel

Katja Weisel

Publications by authors named "Katja Weisel"

Are you Katja Weisel?   Register this Author

100Publications

3503Reads

24Profile Views

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.

Qual Life Res 2019 Sep 24. Epub 2019 Sep 24.

Internal Medicine V and National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-019-02307-5DOI Listing
September 2019

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

N Engl J Med 2019 08;381(8):727-738

From the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (A.C., S.P., S.J.), and New York University Langone Medical Center (D.K.) - both in New York; the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.T.V.); the School of Medicine, National and Kapodistrian University of Athens, Athens (M.G., M. Dimopoulos); the Winship Cancer Institute, Emory University, Atlanta (A.K.N., S.L.); Massachusetts General Hospital Cancer Center (A.J.Y.), Tufts Medical Center (R.L.C.), and the Dana-Farber Cancer Institute (P.G.R.), Boston, and Karyopharm Therapeutics, Newton (M.G.K., S.S., L.L., S. Tang, C.P., J.-R.S.-M., M.C., H.C., Y.L., J.S.) - all in Massachusetts; Johns Hopkins University, Baltimore (C.A.H.); the University of Nantes, Nantes (P.M.), Hôpital Necker (L.F.), Hôpital Saint-Antoine (M.M.), and La Pitié-Salpêtrière Hospital (S.C.), Paris, University Hospital, Lille (T.F.), Centre Hospitalier Lyon Sud, Pierre-Benite (L.K.), and Centre Hospitalo-Universitaire Vandoeuvre-lès-Nancy, Nancy (A.P.) - all in France; the Mayo Clinic, Rochester, MN (D.D.); the University of Michigan, Ann Arbor (C.C.); the Mayo Clinic of Arizona, Phoenix (A.K.S.); Hackensack University Medical Center, Hackensack, NJ (J.R.); Washington University School of Medicine, St. Louis (R.V.); Lineberger Comprehensive Cancer Center at University of North Carolina-Chapel Hill, Chapel Hill (S. Tuchman); the University of Heidelberg, Heidelberg (M.S.R.), University Medical Center Hamburg-Eppendorf, Hamburg (K.C.W.), the University of Tübingen, Tübingen (K.C.W.), University Hospital Würzburg, Würzburg (M.S.), the University of Freiburg, Freiburg (M.E.), and Gemeinschaftspraxis Hämatologie-Onkologie, Dresden (T.I.) - all in Germany; the University of Leuven, Leuven (M. Delforge), Institut Jules Bordet, Université Libre de Bruxelles, Brussels (N.M.), University Hospital Ghent, Ghent (P.V.), and Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Yvoir (C.D.) - all in Belgium; Vanderbilt University Medical Center, Nashville (R.F.C.); Sylvester Cancer Center, University of Miami, Miami (J.E.H.); the University of Alabama at Birmingham, Birmingham (L.J.C.); Yale School of Medicine, New Haven, CT (T.L.P.); Baylor University Medical Center, Dallas (M.L.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (G.S.); and University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria (K.P.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1903455
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1903455DOI Listing
August 2019

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med 2019 05;380(22):2104-2115

From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La Roche sur Yon (M.T.), CHU de Caen, Caen (M.M.), Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris (L.F.), and Department of Hematology, CHU la Miletrie and INSERM CIC 1402, Poitiers (X.L.) - all in France; the Department of Hematology, Mayo Clinic Rochester, Rochester, MN (S.K.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.); Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB (N.B.), and the Division of Medical Oncology, University of Alberta, Edmonton (C.P.V.) - both in Canada; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (S.B.); Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia (H.Q.); University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg (H.G.), and the Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (K.W.) - both in Germany; Department of Medicine-Haematology, National University of Ireland, Galway (M.O.); Florida Cancer Specialists and Research Institute, St. Petersburg (J.R.M.); the Department of Hematology-Oncology, Massachusetts General Hospital, Boston (N.R.); Genmab US, Princeton (T.A.), and Janssen Research and Development, Raritan (J.W., R.K.) - both in New Jersey; Janssen Research and Development, Spring House, PA (C.C., C.M.U., M.Q.); Janssen Research and Development, Beerse, Belgium (R.V.R.); and Levine Cancer Institute-Atrium Health, Charlotte, NC (S.Z.U.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1817249
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1817249DOI Listing
May 2019

Maintenance and continuous therapy for multiple myeloma.

Expert Rev Anticancer Ther 2018 08 3;18(8):751-764. Epub 2018 Jul 3.

d Department of Haematology , Mater Misericordiae University Hospital, University College Dublin , Dublin , Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1490181DOI Listing
August 2018

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

J Clin Oncol 2018 07 2;36(20):2035-2043. Epub 2018 Feb 2.

Meletios Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Katja Weisel, University Hospital of Tuebingen, Tuebingen, Germany; Niels W.C.J. van de Donk, VU Universiteit Medical Center, Amsterdam; Pieter Sonneveld, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Karthik Ramasamy, Oxford University Hospital and NIHR BRC Blood Theme, Oxford; Matthew Streetly, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom; Barbara Gamberi, Arcispedale S. Maria Nuova, Reggio Emilia; Massimo Offidani, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona; Antonio Ardizzoia, Oncology Department, ASST Lecco, Lecco, Italy; Frank Bridoux, University Hospital and University of Poitiers, Poitiers, France; Javier de la Rubia, Hematology Service University Hospital Doctor Peset and Universidad Católica de Valencia "San Vicente Mártir," Valencia; Maria-Victoria Mateos, Instituto de Investigación Biomédica de Salamanca and University of Salamanca, Salamanca, Spain; Elisabeth Kueenburg, Shona Collins, Antonia Di Micco, Barbara Rosettani, and Pamela Bacon, Celgene International, Boudry, Switzerland; and Yan Li, Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.1742DOI Listing
July 2018

Corrigendum to "Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography" [Eur. J. Radiol. 85 (December (12)), 2016, 2195-2199].

Eur J Radiol 2018 06 3;103:163. Epub 2018 May 3.

Department of Neuroradiology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2018.04.023DOI Listing
June 2018

Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm.

Eur Radiol 2017 Jul 23;27(7):2969-2977. Epub 2016 Nov 23.

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tübingen, Hoppe-Seyler-Str.3, D-72076, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-016-4642-6DOI Listing
July 2017

Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.

Clin Transplant 2017 07 26;31(7). Epub 2017 May 26.

Department of Medicine II, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ctr.12994DOI Listing
July 2017

Automated "Bone Subtraction" Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma.

Acad Radiol 2017 05 27;24(5):623-632. Epub 2017 Feb 27.

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str.3, 72076 Tübingen, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2016.12.003DOI Listing
May 2017

Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.

Eur J Radiol 2016 Dec 17;85(12):2195-2199. Epub 2016 Oct 17.

Department of Neuroradiology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2016.10.015DOI Listing
December 2016

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date.

Authors:
Katja Weisel

Onco Targets Ther 2016 5;9:6037-6048. Epub 2016 Oct 5.

Department of Hematology/Oncology, University Hospital Tuebingen, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S94531DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063562PMC
October 2016

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Aug;375(8):754-66

From the Department of Hematology, University of Turin, Turin, Italy (A.P.); the Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville (A.C.-K.); Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tuebingen (K.W.), and University Medical Center of the Johannes Gutenberg-University, Third Department of Medicine, Mainz (M.M.) - both in Germany; Winship Cancer Institute, Emory University, Atlanta (A.K.N.); the Department of Hematology and Stem Cell Transplantation, St. László Hospital, Semmelweis University, Budapest, Hungary (T.M.); Ankara University, Department of Hematology, Ankara, Turkey (M.B.); Clinical Department of Hematology, 1st Medical Department, Charles University in Prague, Prague, Czech Republic (I.S.); Irmandade Da Santa Casa De Misericordia De São Paulo, São Paulo (V.H.); University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain (M.V.M.); Weill Cornell Medical College, New York (T.M.M.); Janssen Research and Development, Spring House, PA (M.Q., X.Q., T.A.); Janssen Research and Development, Raritan, NJ (J.S., H.A.); Janssen Research and Development, Beerse, Belgium (W.D.); Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia (A.S.); and the Department of Hematology, Erasmus MC, Rotterdam, the Netherlands (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1606038DOI Listing
August 2016

Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned.

AJR Am J Roentgenol 2016 Jan;206(1):57-63

1 Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tübingen, Hoppe-Seyler-Strasse 3, Tübingen D-72076, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.15.15089DOI Listing
January 2016

Cutaneous presentation of hematological malignancies.

Eur J Dermatol 2013 May-Jun;23(3):372-7

Department of Dermatology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2013.2010DOI Listing
November 2015

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

Blood 2015 Sep 2;126(10):1203-13. Epub 2015 Jul 2.

Institute for Cell Biology, Department of Immunology, and Cancer Immunotherapy Unit, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-04-640532DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608392PMC
September 2015

Improvement of diagnostic confidence for detection of multiple myeloma involvement of the ribs by a new CT software generating rib unfolded images: Comparison with 5- and 1-mm axial images.

Skeletal Radiol 2015 Jul 2;44(7):971-9. Epub 2015 Apr 2.

Department of diagnostic and interventional radiology, Eberhard Karls University Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00256-015-2131-7DOI Listing
July 2015

Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion.

Transfusion 2015 Mar 23;55(3):605-10. Epub 2014 Sep 23.

Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.12882DOI Listing
March 2015

Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma.

AJR Am J Roentgenol 2015 Mar;204(3):W324-31

1 Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str 3, 72076 Tübingen, Germany.

View Article

Download full-text PDF

Source
http://www.ajronline.org/doi/10.2214/AJR.14.12613
Publisher Site
http://dx.doi.org/10.2214/AJR.14.12613DOI Listing
March 2015

Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.

Ann Hematol 2014 Dec 1;93(12):1993-9. Epub 2014 Jul 1.

Department of Oncology, Hematology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tubingen, Germany.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00277-014-2149
Web Search
http://link.springer.com/10.1007/s00277-014-2149-2
Publisher Site
http://dx.doi.org/10.1007/s00277-014-2149-2DOI Listing
December 2014

Lenalidomide.

Recent Results Cancer Res 2014 ;201:347-57

Department of Oncology, Hematology and Immunology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 10, 72076, Tuebingen, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-54490-3_21DOI Listing
September 2014

Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report.

BMC Res Notes 2014 May 23;7:313. Epub 2014 May 23.

Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology, Medical Center II, South West German Comprehensive Cancer Center, University Hospital of Tuebingen, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-0500-7-313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039653PMC
May 2014

Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.

Clin Lymphoma Myeloma Leuk 2014 Feb 26;14(1):e7-e11. Epub 2013 Oct 26.

Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.07.101DOI Listing
February 2014

Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.

AJR Am J Roentgenol 2014 Jan;202(1):170-9

1 Department of Diagnostic Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.12.10367DOI Listing
January 2014

The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas.

Hum Pathol 2013 Sep 2;44(9):1817-26. Epub 2013 May 2.

Institute of Pathology, Comprehensive Cancer Center, University of Tübingen, D-72076 Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2013.02.004DOI Listing
September 2013

Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.

Transpl Immunol 2012 Jun 2;26(4):171-5. Epub 2012 Feb 2.

Department of Endocrinology and Diabetology, Angiology, Nephrology and Clinical Chemistry, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S096632741200011
Publisher Site
http://dx.doi.org/10.1016/j.trim.2012.01.002DOI Listing
June 2012

Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.

Clin Lymphoma Myeloma Leuk 2012 Jun 16;12(3):191-6. Epub 2012 Feb 16.

Division of Hematology, Oncology and Immunology, Medical Department, University Hospital of Tübingen, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S215226501200002
Publisher Site
http://dx.doi.org/10.1016/j.clml.2012.01.001DOI Listing
June 2012

Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.

Ann Hematol 2012 May 15;91(5):729-735. Epub 2011 Dec 15.

Department of Hematology, Oncology and Immunology, University of Tübingen, Otfried-Müller-Strasse 10, 72076, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-011-1383-0DOI Listing
May 2012

Osteoprotegerin positively regulates hematopoietic progenitor cells.

Curr Stem Cell Res Ther 2012 Jan;7(1):72-7

University of Tübingen, Medical Center, Department of Hematology, Oncology and Immunology, Germany.

View Article

Download full-text PDF

Source
January 2012

Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?

Acad Radiol 2012 Jan;19(1):89-94

Department of Diagnostic Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2011.09.016DOI Listing
January 2012

Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results.

AJR Am J Roentgenol 2011 Jun;196(6):W790-5

Department of Diagnostic Radiology, Eberhard-KarlsUniversity, Hoppe-Seyler-Strasse 3, Tuebingen 72076, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.10.5979DOI Listing
June 2011

Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.

Eur Radiol 2010 Dec 1;20(12):2899-906. Epub 2010 Jul 1.

Department of Diagnostic and Interventional Radiology, Eberhard-Karls University, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-010-1870-zDOI Listing
December 2010

Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging: a feasibility study.

Acad Radiol 2010 Nov;17(11):1326-33

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str.3, 72076 Tuebingen, Germany.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10766332100041
Publisher Site
http://dx.doi.org/10.1016/j.acra.2010.08.002DOI Listing
November 2010

Imaging findings in relapsing multiple myeloma.

Br J Haematol 2010 Aug 26;150(4):388. Epub 2009 Mar 26.

Department of Diagnostic Radiology, Eberhard Karls University Hospital, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.07681.xDOI Listing
August 2010

Wnt1 overexpression leads to enforced cardiomyogenesis and inhibition of hematopoiesis in murine embryonic stem cells.

Stem Cells Dev 2010 May;19(5):745-51

University of Tübingen, Medical Center, Department of Hematology, Oncology and Immunology, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/scd.2008.0356DOI Listing
May 2010

Rhabdomyolysis and acute kidney injury.

N Engl J Med 2009 Oct;361(14):1412; author reply 1412-3

View Article

Download full-text PDF

Source
October 2009

Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease.

AJR Am J Roentgenol 2009 Sep;193(3):656-61

Department of Diagnostic Radiology, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.08.2002DOI Listing
September 2009

International Symposium and Workshop on hematopoietic stem cells VII, University of Tübingen, Germany, September 18-20, 2008.

Ann N Y Acad Sci 2009 Sep;1176:1-17

Department of Hematology, Oncology and Immunology, University Medical Center II, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2009.05130.xDOI Listing
September 2009